Research Progress on High-risk Factors, Prevention and Treatment of Ovarian Cancer

DOI: https://doi.org/10.62517/jmhs.202605211

Author(s)

Jiaxuan Qi

Affiliation(s)

Clinical Medicine, Mudanjiang Medical College, Mudanjiang University, Mudanjiang, Daqing, Heilongjiang, China

Abstract

Based on the relevant international literature of the past five years, this paper summarizes the research progress in the fields of risk assessment, chemoprevention, and early screening. The high-risk factors for ovarian cancer are complex and diverse, and genetic factors, hormonal reproductive factors, and lifestyle factors all play a role in its occurrence.

Keywords

Risk Assessment; Chemoprevention; Early Screening; Genetic Factors; Hormonal Reproductive Factors

References

[1] Antoniou, A. C., et al. (2014). Average risks of breast and ovarian cancer asso ciated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22studies.American Journal of Human Genetics,72(5),1117-1130. [2] Bradshaw, P. T., et al. (2010). Body size and composition and risk of epithet lial ovarian cancer.American Journal of Epidemiology, 171(4),416-426. [3] Chen,W. Y., et al. (2013). Non-steroidal anti-inflammatory drgs and risk of epithelial ovarian cancer: a meta-analysis.British Journal of Cancer,108(1),188-196. [4] Christensen, B. C., et al. (2020). Cell-free DNA methylation-based detection of ovarian cancer in plasma.Nature Communications, 11(1),1-10. [5] Hankinson,S.E.,et al.(2014).Epidemiology and prevention of epithelial ovarian cancer.B est Practice & Research Clinical Obstetrics & Gynaecology, 28(3),303-318. [6] Johnson, C. H., et al. (2014). Vitamin D and risk of epithelial ovarian cancer: a s ystematic review and meta-analysis.Cancer Causes & Control,25(10),1277-1292. [7] Jones,R. W., et al.(2009).Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.Histopathology,54(1),10-23. [8] Kastrinos, F., et al. (2009). Cancer risks for mnale carriers of germline muta tions in MLH1, MSH2, and MSH6:data from the Colon Cancer Family Registry.Journal of Clinical Oncology,27(5),730-736. [9] Kindelberger, D. W., et al. (2007). Intraepithelial carcinoma of the fallopian tube: a possible precursor to high-grade serous carcinoma of the ovary.American Journal of Surgical Pathology, 31(1),161-166. [10] Kuroda, Y.,et al. (2011). The origin and pathogenesis of epithelial ovarian canc er: a proposed unifying theory.American Journal of Pathology,179(4),1888-1898. [11] Matulonis, U. A., et al. (2018). Nivolmab in recurrent platinum-resistant ovarian cancer: an open-label,multicentre,phase 2 trial.The Lancet Oncology,19(5),680-68 9. [12] Menon, U., et al.(2015). Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.The Lancet, 385(9972), 925-933. [13] Moore, K. N., et al. (2018). Niraparib maintenance therapy in platinum-sens itive, recurrent ovarian cancer.New England Journal of Medicine,379(25),2485-2496. [14] NCCN Guidelines.(2023).Ovarian Cancer Screening,Version 1.2023. National Comprehensive Cancer Network,Inc. [15] Penson, R. T., et al. (2019). Olaparib plus bevacizumab as first-line maintenance in ovarian cancer.New England Journal of Medicine, 381(25), 2416-2428. [16] Pharoah, P. D., et al. (2013). Genome-wide association studies a nd risk prediction in ovariancancer.Gynecologic Oncology, 130(3),501-507. [17] Powell, M. A., et al.(2015). Risk-reducing salpingo-oophorectomy for the prevention of BRCA1 and BRCA2-associated breast and gynecologic cancer: a systematic review and meta-analysis. JAMA,304(9),967-975. [18] Riman, T.J., et al. (2004).Age at menarche, age at menopause, height, and risk of epithelial ovarian cancer:a prospective cohort study.British Journal of Cancer, 90(1), 195-200. [19] Siegel, R. L., et al.(2023). Cancer statistics,2023.CA:A Cancer Journal for Clinicians, 73(1),17-48. [20] Talukdar, S., et al.(2014).Reproductive factors, & nbsp; hormonal exposures, and r isk of epithelial ovarian cancer:a population-based case-control study in India. Asian Pacific Journal of Cancer Prevention,15(19),8183-8188.